News / Korea / yonhap_finance
Kiwoom Securities: Interojo Poised for Revaluation Amid Beauty Lens Market Boom
Health Technology · Medical Specialties · yonhap_finance · 2026-09-10
119610
Kiwoom Securities projects a valuation boost for Interojo, citing strong Japanese exports, retail expansion, and upcoming U.S. FDA product approvals.
What Happened
Valuation Reassessment: Kiwoom Securities suggests that Interojo is well-positioned for a revaluation, leveraging its strong manufacturing capabilities in the booming beauty lens sector. As private equity capital flows into the market, Interojo's brand strength is expected to drive significant corporate value growth.
Earnings Recovery: The company is expected to see a strong rebound in Q3 earnings, driven by robust sales in Japan. New product lines, specifically axis-stabilizing lenses, have gained traction in major Japanese retail chains, leading to consistent follow-up orders.
Strategic Expansion: Interojo is actively expanding its domestic footprint with its 'Clalen Studio' retail stores. Simultaneously, the company is preparing for further U.S. market penetration, with additional FDA approvals for silicone-based color daily lenses expected in the fourth quarter.
Market Outlook: While noting some concerns regarding inventory turnover, analysts remain optimistic about the company's business normalization. The combination of differentiated product launches and successful market expansion supports a positive long-term outlook.